AAV serotype 2 vectors preferentially integrate into active genes in mice
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated virus serotype 2 (rAAV2) is a promising vector for gene therapy because it can achieve long-term stable transgene expression in animals and human subjects after direct administration of vectors into various target tissues. In the liver, although stable transgene expression primarily results from extrachromosomal vector genomes, a series of experiments has shown that vector genomes integrate into host chromosomes in hepatocytes at a low frequency. Despite the low integration efficiency, recent reports of retroviral insertional mutagenesis in mice and two human subjects have raised concerns about the potential for rAAV2-mediated insertional mutagenesis. Here we characterize rAAV2-targeted chromosomal integration sites isolated from selected or non-selected hepatocytes in vector-injected mouse livers. We document frequent chromosomal deletions of up to 2 kb at integration sites (14 of 14 integrations, 100%; most of the deletions were <0.3 kb) and preferred integration into genes (21 of 29 integrations, 72%). In addition, all of the targeted genes analyzed (20 of 20 targeted genes, 100%) were expressed in the liver. This is the first report to our knowledge on host chromosomal effects of rAAV2 integration in animals, and it provides insights into the nature of rAAV2 vector integration into chromosomes in quiescent somatic cells in animals and human subjects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Yet, follow-up studies indicated that 53-62% of rAAV integrations in the liver fused into actively-transcribed genes, and 3-8% into ribosomal DNA [247].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [247]
In the citing paper
“preclinical data suggest AAV integration events occur in a dose-dependent manner with a preference for integration at sites of active transcription, tissue-specific promoters are protective against oncogenesis.178, 179, 180”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [180]
In the citing paper
“This number is similar to multiple estimates of random integration of AAV8 from the literature.35”
From Adeno‐associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo†‡ (2010) · cites this paper as [35]
Citations
Cites
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
The sequence of the human genome
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001) · Science · doi:10.1126/science.1058040 · Cited by 13,909
Initial sequencing and comparative analysis of the mouse genome
Mouse Genome Sequencing Consortium (2002) · Nature · doi:10.1038/nature01262 · Cited by 7,187
HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Large-scale analysis of the human and mouse transcriptomes
Su, A. I., Cooke, M. P., Ching, K. A., Hakak, Y., Walker, J. R., Wiltshire, T., Orth, A. P., Vega, R. G., Sapinoso, L. M., Moqrich, A., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012025199 · Cited by 1,466
Kay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022 · cited 1×
“jpg" NDATA ITEM> ]> Recombinant adeno-associated virus serotype 2 (rAAV2) is a promising vector for gene therapy because it can achieve long-term stable transgene expression in animals and human subjects after direct administration of vectors into various target tissue”
BackgroundSelf-citationOverturf, K., Al-Dhalimy, M., Tanguay, R., Brantly, M., Ou, C.-N., Finegold, M., & Grompe, M. (1996) · Nature Genetics · doi:10.1038/ng0396-266 · Cited by 549 · cited 1×
“Because there is a selective repopulation of stable genetically modified FAH-positive hepatocytes in HTI mouse liver”
BackgroundSelf-citationMurine leukemia induced by retroviral gene marking
Li, Z., Düllmann, J., Schiedlmeier, B., Schmidt, M., von Kalle, C., Meyer, J., Forster, M., Stocking, C., Wahlers, A., Frank, O., et al. (2002) · Science · doi:10.1126/science.1068893 · Cited by 525 · cited 1×
“Despite the low integration efficiency, recent reports of retroviral insertional mutagenesis in mic”
BackgroundNakai, H., Yant, S. R., Storm, T. A., Fuess, S., Meuse, L., & Kay, M. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6969-6976.2001 · Cited by 478 · cited 1×
“In the liver, although stable transgene expression primarily results from extrachromosomal vector genome”
BackgroundSelf-citationSOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data
Diehn, M. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg014 · Cited by 428 · cited 1×
“We assessed the transcriptional activity of each targeted gene using web-based public databases and browsers: NCBI UniGene, SOURC”
Method
Cited by
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362
“Although rare, there have been reports of rAAV vector integration into animal model genomes with subsequent genotoxicities [98, 99].”
BackgroundTherapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Ponzoni, M., Bartholomae, C., Sergi, L. S., Benedicenti, F., Ambrosi, A., Di Serio, C., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1216 · Cited by 701
Self-citationGENE THERAPY: Twenty-First Century Medicine
Verma, I. M., & Weitzman, M. D. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.050304.091637 · Cited by 616
Towards safe, non-viral therapeutic gene expression in humans
Glover, D. J., Lipps, H. J., & Jans, D. A. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1577 · Cited by 598
In vivo genome editing restores haemostasis in a mouse model of haemophilia
Li, H., Haurigot, V., Doyon, Y., Li, T., Wong, S. Y., Bhagwat, A. S., Malani, N., Anguela, X. M., Sharma, R., Ivanciu, L., et al. (2011) · Nature · doi:10.1038/nature10177 · Cited by 548
Self-complementary AAV vectors; advances and applications
McCarty, D. M. (2008) · Molecular Therapy · doi:10.1038/mt.2008.171 · Cited by 515
Integration of Adeno-Associated Virus (AAV) and Recombinant AAV Vectors
McCarty, D. M., Young, S. M., & Samulski, R. J. (2004) · Annual Review of Genetics · doi:10.1146/annurev.genet.37.110801.143717 · Cited by 450
Genome-wide analysis of retroviral DNA integration
Bushman, F., Lewinski, M., Ciuffi, A., Barr, S., Leipzig, J., Hannenhalli, S., & Hoffmann, C. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1263 · Cited by 422
“This notion is supported by genome-wide studies, as integration in transcription units is favoured in all the data sets for retroviruses and other integrating element”
BackgroundVector design influences hepatic genotoxicity after adeno-associated virus gene therapy
Chandler, R. J., LaFave, M. C., Varshney, G. K., Trivedi, N. S., Carrillo-Carrasco, N., Senac, J. S., Wu, W., Hoffmann, V., Elkahloun, A. G., Burgess, S. M., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79213 · Cited by 403
“While AAV is known to have a preference to integrate into actively transcribed genes (30), we are unaware of any reports that correlate higher tissue-specific gene expression with increased AAV integration frequency.”
Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality
Hudry, E., & Vandenberghe, L. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.017 · Cited by 369
Mutagenesis and Oncogenesis by Chromosomal Insertion of Gene Transfer Vectors
Baum, C., Kustikova, O., Modlich, U., Li, Z., & Fehse, B. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.253 · Cited by 360
“…largest study available to date used a shuttle plasmid approach to recover close to 1000 AAV vector insertions, showing that there is no profound preference to integrate within transcription units (Miller et al ., 2005), in contrast to previous reports for liver tissue (Nakai et al ., 2003, 2005).”
Occurrence of leukaemia following gene therapy of X-linked SCID
Kohn, D. B., Sadelain, M., & Glorioso, J. C. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1122 · Cited by 344
“Adeno-associated virus (AAV) vectors have also been created that can integrate into the host chromosomes in a non-directed manne”
BackgroundWang, Z., Troilo, P. J., Wang, X., Griffiths, T. G., Pacchione, S. J., Barnum, A. B., Harper, L. B., Pauley, C. J., Niu, Z., Denisova, L., et al. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302213 · Cited by 322
High-Resolution Genome-Wide Mapping of Transposon Integration in Mammals
Yant, S. R., Wu, X., Huang, Y., Garrison, B., Burgess, S. M., & Kay, M. A. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.6.2085-2094.2005 · Cited by 318
“3), we also investigated whether SB integration showed any bias toward important regulatory sequences, as recently reported for recombinant MLV- and AAV-based vectors (36, 38, 39, 58).”
BackgroundResultInfluentialSelf-citationAdeno-Associated Virus Vector Genomes Persist as Episomal Chromatin in Primate Muscle
Penaud-Budloo, M., Le Guiner, C., Nowrouzi, A., Toromanoff, A., Chérel, Y., Chenuaud, P., Schmidt, M., von Kalle, C., Rolling, F., Moullier, P., et al. (2008) · Journal of Virology · doi:10.1128/jvi.00649-08 · Cited by 317
Gene therapy for lysosomal storage diseases
Sands, M. S., & Davidson, B. L. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.006 · Cited by 285
Adeno-associated virus: from defective virus to effective vector
Gonçalves, M. A. (2005) · Virology Journal · doi:10.1186/1743-422x-2-43 · Cited by 264
“Backed by the complete mouse genome sequence, researchers could establish that a significant proportion of rAAV DNA integration events occur in regions that are transcriptionally active in murine hepatocytes [85].”
BackgroundNiemeyer, G. P., Herzog, R. W., Mount, J., Arruda, V. R., Tillson, D. M., Hathcock, J., van Ginkel, F. W., High, K. A., & Lothrop, C. D. (2009) · Blood · doi:10.1182/blood-2008-10-181479 · Cited by 276
Adeno-associated virus vectors integrate at chromosome breakage sites
Miller, D. G., Petek, L. M., & Russell, D. W. (2004) · Nature Genetics · doi:10.1038/ng1380 · Cited by 266
“The preference for integration at transcribed sequence”
Popa, O., Hazkani-Covo, E., Landan, G., Martin, W., & Dagan, T. (2011) · Genome Research · doi:10.1101/gr.115592.110 · Cited by 240
Integration Specificity of Phage ϕC31 Integrase in the Human Genome
Chalberg, T. W., Portlock, J. L., Olivares, E. C., Thyagarajan, B., Kirby, P. J., Hillman, R. T., Hoelters, J., & Calos, M. P. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.11.098 · Cited by 237
Assessing the potential for AAV vector genotoxicity in a murine model
Li, H., Malani, N., Hamilton, S. R., Schlachterman, A., Bussadori, G., Edmonson, S. E., Shah, R., Arruda, V. R., Mingozzi, F., Fraser Wright, J., et al. (2011) · Blood · doi:10.1182/blood-2010-08-302729 · Cited by 236
Sleeping Beauty Transposition: Biology and Applications for Molecular Therapy
Izsvák, Z., & Ivics, Z. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2003.11.009 · Cited by 230
Recombinant Adeno-associated Virus Transduction and Integration
Schultz, B. R., & Chamberlain, J. S. (2008) · Molecular Therapy · doi:10.1038/mt.2008.103 · Cited by 215
Chance or necessity? Insertional Mutagenesis in Gene Therapy and Its Consequences
Baum, C., von Kalle, C., Staal, F. J. T., Li, Z., Fehse, B., Schmidt, M., Weerkamp, F., Karlsson, S., Wagemaker, G., & Williams, D. A. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2003.10.013 · Cited by 225
“Interestingly, the likelihood of insertions into active genes seems to be even more pronounced when using adeno-associated viruses as vectors, which represent an interesting alternative to retroviruses for several nonhematopoietic target tissues [16].”
BackgroundBushman, F. D. (2003) · Cell · doi:10.1016/s0092-8674(03)00760-8 · Cited by 221
“AAV was recently found to favor integration in targeting specificities for the HERVs are unknown, so active genes in a liver gene therapy model (Nakai et al., 2003).they might have favored initial integration in intergenic Zhu, Y., Zou, S., Wright, D.A., and Voytas, D.F. (1999).”
BackgroundSabatino, D. E., Bushman, F. D., Chandler, R. J., Crystal, R. G., Davidson, B. L., Dolmetsch, R., Eggan, K. C., Gao, G., Gil-Farina, I., Kay, M. A., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.06.004 · Cited by 212
“These go on to form ds circular monomers and DNA concatemers directed by host DNA polymerases and DNA repair pathways.(17,18) WT AAV can be maintained as an episome or integrate into the target cell genome mediated by Rep occurring preferentially at a locus on chromosome 19 in humans and also at other chromosome locat…”
BackgroundInfluentialSelf-citationDavidoff, A. M., Gray, J. T., Ng, C. Y. C., Zhang, Y., Zhou, J., Spence, Y., Bakar, Y., & Nathwani, A. C. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.12.022 · Cited by 218
The sound of silence: Transgene silencing in mammalian cell engineering
Cabrera, A., Edelstein, H. I., Glykofrydis, F., Love, K. S., Palacios, S., Tycko, J., Zhang, M., Lensch, S., Shields, C. E., Livingston, M., et al. (2022) · Cell Systems · doi:10.1016/j.cels.2022.11.005 · Cited by 199
George, L. A., Ragni, M. V., Rasko, J. E. J., Raffini, L. J., Samelson-Jones, B. J., Ozelo, M., Hazbon, M., Runowski, A. R., Wellman, J. A., Wachtel, K., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.001 · Cited by 213
“Available data suggest that integration events occur in a dose-dependent manner, preferentially at sites of active transcription.(12,13,17) Experiments in mice suggest that the use of tissue-specific promoters (as opposed to housekeeping promoters) reduces the risk of tumor formation as a consequence of integration.”
BackgroundRecombinant Adeno-Associated Viral Integration and Genotoxicity: Insights from Animal Models
Chandler, R. J., Sands, M. S., & Venditti, C. P. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.009 · Cited by 203
“21 The rAAV vectors’ reduced ability to integrate also means that the therapeutic transgene exists predominantly in the host cell nucleus as non-replicating episomes.”
A Transposon and Transposase System for Human Application
Hackett, P. B., Largaespada, D. A., & Cooper, L. J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.2 · Cited by 206
(2009) · PubMed
Recent developments in adeno‐associated virus vector technology
Büning, H., Perabo, L., Coutelle, O., Quadt‐Humme, S., & Hallek, M. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1205 · Cited by 187
“chromosomal deletions and rearrangements [152] and that integration occurs mainly into active genes [153].”
BackgroundBroekman, M. L. D., Comer, L. A., Hyman, B. T., & Sena-Esteves, M. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2005.11.057 · Cited by 200
Large‐scale molecular characterization of adeno‐associated virus vector integration in mouse liver
Nakai, H., Wu, X., Fuess, S., Storm, T. A., Munroe, D., Montini, E., Burgess, S. M., Grompe, M., & Kay, M. A. (2005) · Journal of Virology · doi:10.1128/jvi.79.6.3606-3614.2005 · Cited by 190
“The 14 integration events previously isolated from mouse A (22) were included in the present study.”
BackgroundMethodInfluentialSelf-citationViral vectors for therapy of neurologic diseases
Choudhury, S. R., Hudry, E., Maguire, C. A., Sena-Esteves, M., Breakefield, X. O., & Grandi, P. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.02.013 · Cited by 190
“, 2005) and transcriptionally active regions of the genome (Nakai et al., 2003).”
BackgroundLipid nanoparticle-mediated drug delivery to the brain
Khare, P., Edgecomb, S. X., Hamadani, C. M., Tanner, E. E. L., & S Manickam, D. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114861 · Cited by 187
Adeno-Associated Virus Integration: Virus versus Vector
Smith, R. H. (2008) · Gene Therapy · doi:10.1038/gt.2008.55 · Cited by 178
A largely random AAV integration profile after LPLD gene therapy
Kaeppel, C., Beattie, S. G., Fronza, R., van Logtenstein, R., Salmon, F., Schmidt, S., Wolf, S., Nowrouzi, A., Glimm, H., von Kalle, C., et al. (2013) · Nature Medicine · doi:10.1038/nm.3230 · Cited by 176
Large-Scale Analysis of Adeno-Associated Virus Vector Integration Sites in Normal Human Cells
Miller, D. G., Trobridge, G. D., Petek, L. M., Jacobs, M. A., Kaul, R., & Russell, D. W. (2005) · Journal of Virology · doi:10.1128/jvi.79.17.11434-11442.2005 · Cited by 171
“be deleted or rearranged (25, 26, 29), although it is not known”
BackgroundResultrAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
Shen, W., Liu, S., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001263 · Cited by 173
Treatment of human disease by adeno-associated viral gene transfer
Warrington, K. H., & Herzog, R. W. (2006) · Human Genetics · doi:10.1007/s00439-006-0165-6 · Cited by 155
“…episomal persistence and low frequency of integration (only 5% of stably transduced hepatocytes have integrated vector genomes, perhaps even less in transduced skeletal muscle fibers using AAV-2 vectors) (Duan et al. 1998a; Nakai et al. 1999, 2001, 2003a, b; Schnepp et al. 2005; Yue and Duan 2003).”
BackgroundAnalysis of Tumors Arising in Male B6C3F1 Mice with and without AAV Vector Delivery to Liver
Bell, P., Moscioni, A. D., McCarter, R. J., Wu, D., Gao, G., Hoang, A., Sanmiguel, J. C., Sun, X., Wivel, N. A., Raper, S. E., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.008 · Cited by 149
“Since AAV has the potential to integrate into the genome of its host cell [1–3], the risk of tumor formation upon delivery of AAV vectors has been recently discussed, especially after a report in which mice with mucopolysaccharidosis type VII, which are deficient in the enzyme h-glucuronidase (GUSB), developed tumors…”
BackgroundEvaluation of Risks Related to the Use of Adeno-Associated Virus-Based Vectors
Tenenbaum, L., Lehtonen, E., & Monahan, P. E. (2003) · Current Gene Therapy · doi:10.2174/1566523034578131 · Cited by 148
“…Miller et al., 2002; Huser et al.2002] or in mice (which do not carry sequences homologous to the human AAVS1 integration site) [Nakai et al., 1999; Nakai et al. 2003] suggest that rAAV’s “random” integration favors transcriptionally active regions of the host genome [Rivadeneira et al. 1998;…”
BackgroundBell, J. B., Podetz-Pedersen, K. M., Aronovich, E. L., Belur, L. R., McIvor, R. S., & Hackett, P. B. (2007) · Nature Protocols · doi:10.1038/nprot.2007.471 · Cited by 145
Sleeping Beauty Transposon‐Mediated Gene Therapy for Prolonged Expression
Hackett, P. B., Ekker, S. C., Largaespada, D. A., & McIvor, R. S. (2005) · Advances in genetics · doi:10.1016/s0065-2660(05)54009-4 · Cited by 145
Povedano, J. M., Martinez, P., Serrano, R., Tejera, Á., Gómez-López, G., Bobadilla, M., Flores, J. M., Bosch, F., & Blasco, M. A. (2018) · eLife · doi:10.7554/elife.31299 · Cited by 139
“As a note of caution regarding the use of AAV vectors, it has been shown that transcriptional active host loci and DNA repair factors impact on rAAV vector integration in the host genome as well as on vector maintenance as linear or circular episomes, affecting thereby the duration of expression and mutagenic potentia…”
BackgroundAdeno-Associated Virus Gene Therapy for Hemophilia
Samelson‐Jones, B. J., & George, L. A. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-033013 · Cited by 150
No Evidence for Tumorigenesis of AAV Vectors in a Large-Scale Study in Mice
Bell, P., Wang, L., Lebherz, C., Flieder, D. B., Bove, M. S., Wu, D., Gao, G. P., Wilson, J. M., & Wivel, N. A. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.03.020 · Cited by 135
Adeno‐associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo†‡
Paulk, N. K., Wursthorn, K., Wang, Z., Finegold, M. J., Kay, M. A., & Grompe, M. (2010) · Hepatology · doi:10.1002/hep.23481 · Cited by 135
Self-citationPrecise hit: adeno-associated virus in gene targeting
Vasileva, A., & Jessberger, R. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1266 · Cited by 157
“Up to 72% of rAAV insertions occur preferentially in actively transcribed genes and are associated with genomic deletion”
BackgroundThe state of the art of adeno-associated virus-based vectors in gene therapy
Coura, R., & Nardi, N. (2007) · Virology Journal · doi:10.1186/1743-422x-4-99 · Cited by 130
“And (4), some investigators have shown preferential integration of recombinant AAV2 vectors into transcriptionally active chromatin regions [17,18].”
BackgroundMicroRNA-377 suppresses initiation and progression of esophageal cancer by inhibiting CD133 and VEGF
Li, B., Xu, W., Li, H., Chan, K.-T., Tsao, S. W., Lee, N. P. Y., Law, S. Y.-K., Xu, L., Li, E., Chan, K. W., et al. (2017) · Oncogene · doi:10.1038/onc.2017.29 · Cited by 138
Ferrari, S., Jacob, A., Cesana, D., Laugel, M., Beretta, S., Varesi, A., Unali, G., Conti, A., Canarutto, D., Albano, L., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.09.001 · Cited by 133
Self-citationCalias, P., Papisov, M., Pan, J., Savioli, N., Belov, V., Huang, Y., Lotterhand, J., Alessandrini, M., Liu, N., Fischman, A. J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030341 · Cited by 133
“AAV vectors also integrate into active genes, with frequent chromosomal deletions of up to 2 kB at integration sites [54].”
BackgroundRVG peptide tethered bioreducible polyethylenimine for gene delivery to brain
Son, S., Hwang, D. W., Singha, K., Jeong, J. H., Park, T. G., Lee, D. S., & Kim, W. J. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.011 · Cited by 141
AAV integration in human hepatocytes
Dalwadi, D. A., Calabria, A., Tiyaboonchai, A., Posey, J., Naugler, W. E., Montini, E., & Grompe, M. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.08.031 · Cited by 126
Self-citationNumt-Mediated Double-Strand Break Repair Mitigates Deletions during Primate Genome Evolution
Hazkani‐Covo, E., & Covo, S. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000237 · Cited by 141
“Capture of DNA sequences into chromosomal breaks was shown previously both in cell culture and during chromosomal evolution [12,13,55–58,70].”
BackgroundResultInfluentialRecombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders
Mandel, R. J., Manfredsson, F. P., Foust, K. D., Rising, A., Reimsnider, S., Nash, K., & Burger, C. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.009 · Cited by 126
“Interestingly, the recombinant version of AAV loses much of its capacity to integrate and the genome persists in an episomal form [9,10].”
BackgroundRetroviral vectors: new applications for an old tool
Barquinero, J., Eixarch, H., & Pérez-Melgosa, M. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302363 · Cited by 129
Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions
Riyad, J. M., & Weber, T. (2021) · Gene Therapy · doi:10.1038/s41434-021-00243-z · Cited by 118
Genome Engineering Using Adeno-associated Virus: Basic and Clinical Research Applications
Gaj, T., Epstein, B. E., & Schaffer, D. V. (2016) · Molecular Therapy · doi:10.1038/mt.2015.151 · Cited by 119
Nowrouzi, A., Penaud-Budloo, M., Kaeppel, C., Appelt, U., Le Guiner, C., Moullier, P., Kalle, C. V., Snyder, R. O., & Schmidt, M. (2012) · Molecular Therapy · doi:10.1038/mt.2012.47 · Cited by 111
Grimm, D., Pandey, K., Nakai, H., Storm, T. A., & Kay, M. A. (2006) · Journal of Virology · doi:10.1128/jvi.80.1.426-439.2006 · Cited by 118
“AAV-2 vectors integrate infrequently ( 10%) and via existing duplex DNA breaks (34, 35, 39, 44) and thus in a random and ITR-independent fashion, although integration sites had microhomologies to the AAV-2 ITR and Nakai et al.”
BackgroundSelf-citationHaridhasapavalan, K. K., Borgohain, M. P., Dey, C., Saha, B., Narayan, G., Kumar, S., & Thummer, R. P. (2019) · Gene · doi:10.1016/j.gene.2018.11.069 · Cited by 115
Targeting the heart with gene therapy-optimized gene delivery methods
Müller, O. J., Katus, H. A., & Bekeredjian, R. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.09.021 · Cited by 108
Interactions of viruses with the cellular DNA repair machinery
Weitzman, M. D., Carson, C. T., Schwartz, R. A., & Lilley, C. E. (2004) · DNA repair · doi:10.1016/j.dnarep.2004.03.018 · Cited by 125
Hickman, A. B., Ronning, D. R., Perez, Z. N., Kotin, R. M., & Dyda, F. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00023-1 · Cited by 109
Intravenous, non-viral RNAi gene therapy of brain cancer
Pardridge, W. M. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.7.1103 · Cited by 104
“NAKAI H, MONTINI E, FUESS S et al.: AAV serotype 2 vectors preferentially integrate into active genes in mice.”
BackgroundMashel, T. V., Tarakanchikova, Y. V., Muslimov, A. R., Zyuzin, M. V., Timin, A. S., Lepik, K. V., & Fehse, B. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120282 · Cited by 105
miRNA cassettes in viral vectors: Problems and solutions
Liu, Y. P., & Berkhout, B. (2011) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2011.05.014 · Cited by 109
Targeted modification of mammalian genomes
Sorrell, D. A., & Kolb, A. F. (2005) · Biotechnology Advances · doi:10.1016/j.biotechadv.2005.03.003 · Cited by 110
Site-Specific Integration of Functional Transgenes into the Human Genome by Adeno/AAV Hybrid Vectors
Recchia, A., Perani, L., Sartori, D., Olgiati, C., & Mavilio, F. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.003 · Cited by 92
“…interpreted as the consequence of Rep-independent replication of the single-stranded AAV vector genome during integration [29], most likely mediated by a tran-scription-coupled, double-strand break DNA repair mechanism leading to preferential integration into transcribed chromatin regions [30,31].”
Stephen, S. L., Freestone, K., Dunn, S., Twigg, M. W., Homer‐Vanniasinkam, S., Walker, J. H., Wheatcroft, S. B., & Ponnambalam, S. (2010) · International Journal of Hypertension · doi:10.4061/2010/646929 · Cited by 109
“A slightly higher percentage of adeno-associated viral vector DNA [180, 181] integrated into genes causing chromosomal deletions and translocation [182–184].”
BackgroundSalmon, F., Grosios, K., & Petry, H. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.852065 · Cited by 93
Liu, L., Mah, C. S., & Fletcher, B. S. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.021 · Cited by 102
“While viralbased vectors have shown some success, the utility of several of these vectors has been limited by induction of host immune and inflammatory responses [7,8] as well as the risk of inducing tumorigenic mutations [9,10].”
BackgroundEfficient stable gene transfer into human cells by the Sleeping Beauty transposon vectors
Izsvák, Z. (2009) · Methods · doi:10.1016/j.ymeth.2009.07.001 · Cited by 95
DNA-dependent PK inhibits adeno-associated virus DNA integration
Song, S., Lu, Y., Choi, Y.-K., Han, Y., Tang, Q., Zhao, G., Berns, K. I., & Flotte, T. R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307833100 · Cited by 94
Ertl, H. C. J., & High, K. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.172 · Cited by 94
“31 34 Re-introduction of a helper virus or application of a genotoxic reagent can reactivate AAV replication.”
Adeno-associated Virus as a Mammalian DNA Vector
Salganik, M., Hirsch, M. L., & Samulski, R. J. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.mdna3-0052-2014 · Cited by 87
“In addition, Mre11, a key sensor of damaged DNA normally considered part of the HR pathway, in conjunction with Nbs1 and Rad50, also appears to inhibit AAV transduction (145, 146, 160).”
BackgroundBuck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
“Yet, follow-up studies indicated that 53-62% of rAAV integrations in the liver fused into actively-transcribed genes, and 3-8 % into ribosomal DNA [247].”
BackgroundChromosomal Integration of Adenoviral Vector DNA In Vivo
Stephen, S. L., Montini, E., Sivanandam, V. G., Al-Dhalimy, M., Kestler, H. A., Finegold, M. J., Grompe, M., & Kochanek, S. (2010) · Journal of Virology · doi:10.1128/jvi.00751-10 · Cited by 105
“Detailed information on genotoxicity following gene transfer is available for vectors derived from viruses of the Retroviridae and Parvoviridae families (2, 20, 23, 26, 46).”
BackgroundSelf-citationMolecular Analysis of Chromosomal Rearrangements in Mammalian Cells After ø C31-Mediated Integration
Ehrhardt, A., Engler, J. A., Xu, H., Cherry, A. M., & Kay, M. A. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.1077 · Cited by 86
Self-citationGenetic Modification of T Lymphocytes for Adoptive Immunotherapy
Rössig, C., & Brenner, M. K. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.04.014 · Cited by 88
Ellis, B. L., Hirsch, M. L., Porter, S. N., Samulski, R. J., & Porteus, M. H. (2013) · Gene Therapy · doi:10.1038/gt.2011.211 · Cited by 84
Bacterial NHEJ: a never ending story
Bertrand, C., Thibessard, A., Bruand, C., Lecointe, F., & Leblond, P. (2019) · Molecular Microbiology · doi:10.1111/mmi.14218 · Cited by 94
“…DNA inserted into the genome by NHEJ during evolution include foreign DNA fragments such as mitochondrial DNA, transposable elements, and viral DNA (Moore and Haber, 1996; Ricchetti et al. , 1999; Lin and Waldman, 2001a; Lin and Waldman, 2001b; Nakai et al. , 2003; Hazkani-Covo and Covo, 2008) .”
BackgroundGene therapy progress and prospects: Parkinson's disease
Burton, E. A., Glorioso, J. C., & Fink, D. J. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302116 · Cited by 96
Materials for Improving Immune Cell Transfection
Kumar, A. R. K., Shou, Y., Chan, B., Krishaa, L., & Tay, A. K. P. (2021) · Advanced Materials · doi:10.1002/adma.202007421 · Cited by 85
Harding, C. O., Gillingham, M. B., Hamman, K. J., Clark, H., Daghighi, E., Bird, A., & Koeberl, D. D. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302678 · Cited by 83
Improving miRNA Delivery by Optimizing miRNA Expression Cassettes in Diverse Virus Vectors
Herrera-Carrillo, E., Liu, Y. P., & Berkhout, B. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2017.036 · Cited by 86
Integration target site selection for retroviruses and transposable elements
Wu, X., & Burgess, S. M. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4206-9 · Cited by 95
Sleeping Beauty‐based gene therapy with indoleamine 2,3‐dioxygenase inhibits lung allograft fibrosis
Liu, H., Liu, L., Fletcher, B. S., & Visner, G. A. (2006) · The FASEB Journal · doi:10.1096/fj.06-6228fje · Cited by 81
“These observations are in sharp contrast to viral vector integration, which shows a propensity to integrate into active genes and promoter regions (32, 33).”
ResultStructure-based prediction of insertion-site preferences of transposons into chromosomes
Geurts, A. M., Hackett, C. S., Bell, J. B., Bergemann, T. L., Collier, L. S., Carlson, C. M., Largaespada, D. A., & Hackett, P. B. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl301 · Cited by 80
Episomal Vectors for Gene Therapy
Ehrhardt, A., Haase, R., Schepers, A., Deutsch, M. J., Lipps, H. J., & Baiker, A. E. (2008) · Current Gene Therapy · doi:10.2174/156652308784746440 · Cited by 91
Gene therapy for liver diseases — progress and challenges
Zabaleta, N., Unzu, C., Weber, N. D., & González‐Aseguinolaza, G. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00729-0 · Cited by 80
Parambi, D. G. T., Alharbi, K. S., Kumar, R., Harilal, S., Batiha, G. E., Martins, N. A., Hendawy, O. M., Musa, A., Panda, D. S., & Mathew, B. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02555-y · Cited by 82
Metadata
- Authors
- Nakai, H., Montini, E., Fuess, S., Storm, T. A., Grompe, M., & Kay, M. A.
- Affiliations
- Stanford Medicine (US)
- Oregon Health & Science University (US)
- Corresponding author
- Kay, Mark A
- Venue
- Nature Genetics
- Published
- 2003-06-01
- Volume
- 34
- Issue
- 3
- Pages
- 297-302
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2171427593
- Cited by
- 392
- References
- 29
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 13 · 2023: 12 · 2022: 11 · 2021: 11 · 2020: 18 · 2019: 8 · 2018: 10 · 2017: 10 · 2016: 8 · 2015: 13 · 2014: 8 · 2013: 7 · 2012: 19
- FWCI
- 22.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- AAV2, rAAV2, chromosomal integration, insertional mutagenesis, gene therapy vectors, hepatocytes, liver, somatic cells, transgene expression
- MeSH terms
- Dependovirus, Animals, Base Sequence, Cell Line, Chromosome Deletion, Chromosomes, Female, Genes, Genetic Vectors, Humans, Mice, Inbred C57BL, Molecular Sequence Data, Plasmids, Sequence Homology, Nucleic Acid, Transduction, Genetic, Genetic Therapy, Virus Integration, Gene Transfer Techniques, Transgenes, Hepatocytes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.